REFRACTORY ACUTE LEUKEMIA
Clinical trials for REFRACTORY ACUTE LEUKEMIA explained in plain language.
Never miss a new study
Get alerted when new REFRACTORY ACUTE LEUKEMIA trials appear
Sign up with your email to follow new studies for REFRACTORY ACUTE LEUKEMIA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New hope for kids with tough leukemia: drug combo trial launches
Disease control Recruiting nowThis early-phase study tests a new drug called ziftomenib combined with two standard drugs (venetoclax and azacitidine) in children and young adults aged 2 to 21 whose acute leukemia has returned or not responded to treatment. The main goal is to find the safest dose and watch fo…
Matched conditions: REFRACTORY ACUTE LEUKEMIA
Phase: PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 26, 2026 10:58 UTC
-
New combo therapy offers hope for kids with relapsed leukemia
Disease control Recruiting nowThis early-stage study tests a powerful chemotherapy combination (hyper-CVAD plus venetoclax) in children and young adults whose leukemia has returned or not responded to standard treatment. The main goal is to find a safe dose and monitor side effects. About 22 participants with…
Matched conditions: REFRACTORY ACUTE LEUKEMIA
Phase: PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 22, 2026 14:02 UTC
-
New drug duo targets tough leukemias in early trial
Disease control Recruiting nowThis study tests whether combining two drugs, revumenib and mezigdomide, is safe for people whose acute leukemia has returned or not responded to prior treatment. It includes adults and teens aged 12+ with specific genetic subtypes (KMT2A-r, NUP98-r, or NPM1-m). The first part fi…
Matched conditions: REFRACTORY ACUTE LEUKEMIA
Phase: PHASE1, PHASE2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated May 22, 2026 13:54 UTC